ArticleBioinformation2023
Tumor regression efficacy of
Article in Bioinformation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is of interest to describe the extraction and isolation of ethyl heneicosanoate (EHO) from Punica granatum. L plant leaves. Further, the structure of isolated molecule, EHO was confirmed through various spectroscopic tools viz., infrared (FT-IR), proton NMR and mass spectroscopy. The tumor regression potential of EHO was evaluated against K562 leukemia cancer cells. A significant reduction in the viability and metabolic activity was obtained in vitro for K562 cell lines when treated with EHO molecule. Further, the results depicted that the activities of EHO is directly related to the alkyl chain length. The xenograft model of mice illustrated a lower propensity of tumor growth in the group receiving EHO molecule, compared with the group receiving Bortezomib (positive control). The obtained results suggest that the animals treated with Bortezomib showed a tumor growth inhibition up to 77.51 ± 3.74 whereas, the EHO showed the inhibition up to 23.37 ± 25.44 and 40.64 ± 16.45 % at 200 mg/kg and 400 mg/kg respectively. Moreover, the results indicate that the activity of EHO in the induction of apoptosis in induced leukemia cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.